GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more
GRI Bio Inc. (GRI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.495x
Based on the latest financial reports, GRI Bio Inc. (GRI) has a cash flow conversion efficiency ratio of -0.495x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.97 Million) by net assets ($6.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GRI Bio Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how GRI Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
GRI Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GRI Bio Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Neolife SA
PA:ALNLF
|
0.028x |
|
Vina San Pedro
SN:VSPT
|
0.001x |
|
Genetic Technologies Ltd
NASDAQ:GENE
|
-3.096x |
|
BAB Inc
OTCQB:BABB
|
0.055x |
|
Rovsing A/S
CO:ROV
|
-0.227x |
|
HOV Services Limited
NSE:HOVS
|
-0.052x |
|
Bion Environmental Technologies Inc
OTCQB:BNET
|
0.042x |
|
CanAsia Energy Corp.
PINK:CECAF
|
-0.135x |
Annual Cash Flow Conversion Efficiency for GRI Bio Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of GRI Bio Inc. from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.01 Million | $-10.19 Million | -1.695x | +20.61% |
| 2024-12-31 | $4.03 Million | $-8.61 Million | -2.136x | +93.85% |
| 2023-12-31 | $259.00K | $-8.99 Million | -34.710x | -5298.57% |
| 2022-12-31 | $-1.62 Million | $-1.08 Million | 0.668x | +272.39% |
| 2021-12-31 | $-4.72 Million | $-847.00K | 0.179x | -92.97% |
| 2020-12-31 | $-1.45 Million | $-3.71 Million | 2.549x | +384.06% |
| 2019-12-31 | $3.21 Million | $-2.88 Million | -0.897x | +94.21% |
| 2018-12-31 | $152.94K | $-2.37 Million | -15.503x | -- |